The therapies that have been approved for non-small cell lung cancer stimulate the immune system to attack cancer cells… But what happens when they do too good a job of that and stimulate the immune system to inflame other parts of the body as well? Dr. Michael Shafique from the Moffitt Cancer Center breaks down the most common adverse events to look for in patients with non-small cell lung cancer.